DBVT - DBV Technologies S.A.

NasdaqGS - NasdaqGS Real-time price. Currency in USD

DBV Technologies S.A.

177-181 avenue Pierre Brossolette
Montrouge 92120
France
33 1 55 42 78 78
http://www.dbv-technologies.com

SectorHealthcare
IndustryBiotechnology
Full-time employees315

Key executives

NameTitlePayExercisedYear born
Mr. Daniel TasséCEO & DirectorN/AN/A1960
Dr. Pierre-Henri BenhamouCo-Founder & Member of Scientific Advisory BoardN/AN/A1955
Mr. David SchilanskyDeputy CEO & CFON/AN/A1975
Dr. Laurent MartinDeputy CEO & Responsible PharmacistN/AN/A1967
Dr. Hugh A. SampsonChief Scientific Officer & Member of Scientific Advisory BoardN/AN/A1949
Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E mediated cow's milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include vaccine for respiratory syncytial virus, as well as treatments for Crohn's disease, hemophilia A, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of CMPA in infants and toddlers. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France.

Corporate governance

DBV Technologies S.A.’s ISS governance QualityScore as of 25 June 2019 is 9. The pillar scores are Audit: 1; Board: 9; Shareholder rights: 1; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.
By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes